Condition
Immune-Mediated Hepatitis
Total Trials
4
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Recruiting4
Clinical Trials (4)
Showing 4 of 4 trials
NCT04476563RecruitingPrimary
Checkpoint Inhibitor-induced Liver Injury
NCT06470997RecruitingPrimary
Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
NCT07167251Recruiting
Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids
NCT05484908Not ApplicableRecruitingPrimary
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
Showing all 4 trials